JP2023501722A5 - - Google Patents

Info

Publication number
JP2023501722A5
JP2023501722A5 JP2022528263A JP2022528263A JP2023501722A5 JP 2023501722 A5 JP2023501722 A5 JP 2023501722A5 JP 2022528263 A JP2022528263 A JP 2022528263A JP 2022528263 A JP2022528263 A JP 2022528263A JP 2023501722 A5 JP2023501722 A5 JP 2023501722A5
Authority
JP
Japan
Application number
JP2022528263A
Other languages
Japanese (ja)
Other versions
JP7590430B2 (ja
JPWO2021097325A5 (https=
JP2023501722A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/060557 external-priority patent/WO2021097325A1/en
Publication of JP2023501722A publication Critical patent/JP2023501722A/ja
Publication of JP2023501722A5 publication Critical patent/JP2023501722A5/ja
Publication of JPWO2021097325A5 publication Critical patent/JPWO2021097325A5/ja
Priority to JP2024198993A priority Critical patent/JP2025024094A/ja
Application granted granted Critical
Publication of JP7590430B2 publication Critical patent/JP7590430B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022528263A 2019-11-14 2020-11-13 抗tcr抗体分子およびその使用 Active JP7590430B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024198993A JP2025024094A (ja) 2019-11-14 2024-11-14 抗tcr抗体分子およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962935172P 2019-11-14 2019-11-14
US62/935,172 2019-11-14
US202062956969P 2020-01-03 2020-01-03
US62/956,969 2020-01-03
PCT/US2020/060557 WO2021097325A1 (en) 2019-11-14 2020-11-13 Anti-tcr antibody molecules and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024198993A Division JP2025024094A (ja) 2019-11-14 2024-11-14 抗tcr抗体分子およびその使用

Publications (4)

Publication Number Publication Date
JP2023501722A JP2023501722A (ja) 2023-01-18
JP2023501722A5 true JP2023501722A5 (https=) 2024-05-13
JPWO2021097325A5 JPWO2021097325A5 (https=) 2024-05-13
JP7590430B2 JP7590430B2 (ja) 2024-11-26

Family

ID=75912403

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022528263A Active JP7590430B2 (ja) 2019-11-14 2020-11-13 抗tcr抗体分子およびその使用
JP2024198993A Pending JP2025024094A (ja) 2019-11-14 2024-11-14 抗tcr抗体分子およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024198993A Pending JP2025024094A (ja) 2019-11-14 2024-11-14 抗tcr抗体分子およびその使用

Country Status (8)

Country Link
US (1) US20230048244A1 (https=)
EP (1) EP4058483A4 (https=)
JP (2) JP7590430B2 (https=)
CN (1) CN115003698A (https=)
AU (2) AU2020384369B2 (https=)
CA (1) CA3160997A1 (https=)
GB (1) GB2607452B (https=)
WO (1) WO2021097325A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス,インコーポレーテッド T細胞関連のがん細胞に結合する多機能性分子およびその使用
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
WO2023056556A1 (en) * 2021-10-07 2023-04-13 National Research Council Of Canada Anti-cd3 monoclonal antibodies and therapeutic constructs
WO2023081412A2 (en) * 2021-11-05 2023-05-11 Marengo Therapeutics, Inc. Immune cell populations and uses thereof
EP4601747A1 (en) * 2022-10-12 2025-08-20 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof
AU2024240821A1 (en) 2023-03-23 2025-11-06 Bodhi Bio Llc Compositions and methods for antigen-specific therapy
WO2025051339A1 (en) * 2023-09-05 2025-03-13 Tiber Biotech Srl SINGLE-CHAIN VARIABLE FRAGMENT AND MOLECULES DERIVING THEREFROM THAT BIND FRAGMENT TRVB5-1 OF THE β CHAIN OF HUMAN T-CELL RECEPTOR
WO2025245071A1 (en) * 2024-05-21 2025-11-27 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766947A (en) * 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
US5776459A (en) * 1989-07-19 1998-07-07 Connetics Corporation TCR V beta 5 peptides
AU5245399A (en) * 1998-07-29 2000-02-21 Heska Corporation T cell receptor proteins, nucleic acid molecules, and uses thereof
DK2336187T3 (en) * 2000-06-19 2016-08-22 Beth Israel Deaconess Medical Ct Inc Compositions and Methods of monoclonal and polyclonal antibodies which are specific for T-cell subpopulations
GB0328363D0 (en) * 2003-12-06 2004-01-14 Imp College Innovations Ltd Therapeutically useful molecules
US9018006B2 (en) * 2010-07-23 2015-04-28 The University Of Toledo Stable Tregs and related materials and methods
ES2534782T3 (es) * 2012-02-02 2015-04-28 Baylor College Of Medicine Sistema biológico de administración y expresión basado en adenovirus para uso en el tratamiento de la osteoartritis
SG11201603193PA (en) * 2013-10-30 2016-05-30 Genzyme Corp Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide
WO2016193301A1 (en) * 2015-06-01 2016-12-08 Medigene Immunotherapies Gmbh T-cell receptor specific antibodies
EP3818083A2 (en) * 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
GB2595980B (en) * 2019-01-04 2023-06-14 Marengo Therapeutics Inc Anti-TCR antibody molecules and uses thereof
AU2020226904B2 (en) * 2019-02-21 2025-05-01 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
CN116234829A (zh) * 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
WO2023081412A2 (en) * 2021-11-05 2023-05-11 Marengo Therapeutics, Inc. Immune cell populations and uses thereof

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
JP2023501722A5 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
CL2025003474A1 (es) Sales agonistas de sstr4.
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016375A2 (https=)
BR102021016200A2 (https=)